Laura S Gilchrist1, Lynn Tanner. 1. Hematology and Oncology Program, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN 55404, USA. lsgilchrist@stkate.edu
Abstract
BACKGROUND: Neurotoxicity is a common side-effect of cancer treatment, but no scales have been validated for the pediatric population. The objective of this study was to test the reliability and validity of the pediatric modified-Total Neuropathy Scale (ped-mTNS) to measure chemotherapy-induced peripheral neuropathy in school-aged children. METHODS: Forty-one subjects aged 5-18 years undergoing chemotherapy with vincristine or cisplatin and 41 age- and gender-matched controls completed study measures. Subjects were tested with the ped-mTNS at a specified time during treatment. Standardized measures of balance and hand function were completed concurrently. Internal consistency of the ped-mTNS was evaluated using Chronbach's alpha. Validity was tested by comparing case and control ped-mTNS scores as well as testing the hypothesis that ped-mTNS scores would be associated with scores on tests of balance and manual dexterity. Inter-rater and test-retest reliability were each assessed in a subset of 10 subjects. RESULTS: Twenty-three subjects with acute lymphoblastic leukemia, six with lymphoma, and 12 with solid tumors completed measures along with 41 age- and gender-matched controls. Internal consistency was acceptable with a Chronbach's alpha of 0.76. Children undergoing treatment for cancer had significantly worse scores on the ped-mTNS compared to controls (subjects, 8.7 ± 4.2; controls, 1.4 ± 0.9; p < 0.001). As hypothesized, scores on the ped-mTNS were associated with measures of balance and manual dexterity. Inter-rater and test-retest reliability was acceptable (intraclass correlation coefficients >0.9 each). CONCLUSIONS: The ped-mTNS is a reliable and valid measure of chemotherapy-induced peripheral neuropathy in school-aged children that is associated with relevant functional limitations.
BACKGROUND:Neurotoxicity is a common side-effect of cancer treatment, but no scales have been validated for the pediatric population. The objective of this study was to test the reliability and validity of the pediatric modified-Total Neuropathy Scale (ped-mTNS) to measure chemotherapy-induced peripheral neuropathy in school-aged children. METHODS: Forty-one subjects aged 5-18 years undergoing chemotherapy with vincristine or cisplatin and 41 age- and gender-matched controls completed study measures. Subjects were tested with the ped-mTNS at a specified time during treatment. Standardized measures of balance and hand function were completed concurrently. Internal consistency of the ped-mTNS was evaluated using Chronbach's alpha. Validity was tested by comparing case and control ped-mTNS scores as well as testing the hypothesis that ped-mTNS scores would be associated with scores on tests of balance and manual dexterity. Inter-rater and test-retest reliability were each assessed in a subset of 10 subjects. RESULTS: Twenty-three subjects with acute lymphoblastic leukemia, six with lymphoma, and 12 with solid tumors completed measures along with 41 age- and gender-matched controls. Internal consistency was acceptable with a Chronbach's alpha of 0.76. Children undergoing treatment for cancer had significantly worse scores on the ped-mTNS compared to controls (subjects, 8.7 ± 4.2; controls, 1.4 ± 0.9; p < 0.001). As hypothesized, scores on the ped-mTNS were associated with measures of balance and manual dexterity. Inter-rater and test-retest reliability was acceptable (intraclass correlation coefficients >0.9 each). CONCLUSIONS: The ped-mTNS is a reliable and valid measure of chemotherapy-induced peripheral neuropathy in school-aged children that is associated with relevant functional limitations.
Authors: Ellen M Lavoie Smith; Clare Kuisell; Grace A Kanzawa-Lee; Celia M Bridges; Paola Alberti; Guido Cavaletti; Rima Saad; Susanna Park Journal: Lancet Haematol Date: 2020-05 Impact factor: 18.959
Authors: Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness Journal: Lancet Child Adolesc Health Date: 2018-09-01
Authors: Ellen M Lavoie Smith; Lang Li; ChienWei Chiang; Karin Thomas; Raymond J Hutchinson; Elizabeth M Wells; Richard H Ho; Jodi Skiles; Arindom Chakraborty; Celia M Bridges; Jamie Renbarger Journal: J Peripher Nerv Syst Date: 2015-03 Impact factor: 3.494
Authors: Mitra Varedi; Lu Lu; Carrie R Howell; Robyn E Partin; Melissa M Hudson; Ching-Hon Pui; Kevin R Krull; Leslie L Robison; Kirsten K Ness; Raymond F McKenna Journal: J Clin Oncol Date: 2018-05-29 Impact factor: 44.544
Authors: Jodi L Skiles; ChienWei Chiang; Claire H Li; Steve Martin; Ellen L Smith; Gilbert Olbara; David R Jones; Terry A Vik; Saskia Mostert; Floor Abbink; Gertjan J Kaspers; Lang Li; Festus Njuguna; Tammy J Sajdyk; Jamie L Renbarger Journal: Pediatr Blood Cancer Date: 2017-11-08 Impact factor: 3.167